Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation in AML, MDS/AML and Higher Risk MDS
Age between 18 and 75 years at the time of signing the Informed Consent
Patient is fluent in German
Signed written Informed Consent with the cognitive ability to understand all consequences of trial participation and to comply with all trial related procedures
Diagnosis of AML,MDS/AML (according to ICC 20226) or HRMDS (IPSS-R7 >3.5 or IPSS-M8 >0; according to ICC 20226 and IWG 20232)
APL (AML with t(15;17))
MDS/MPN (ICC 20226)
Karnofsky Performance Index <60%
Patient scheduled for haploidentical allogeneic hematopoetic stem cell transplantation or bone marrow stem cell transplantation